Business Context and Reporting Period
This Form 8-K is filed by Second Sight Medical Products, Inc. (trading symbol: EYES) for the reporting period ending April 1, 2021. The filing addresses the termination of a proposed business combination with Pixium Vision SA ("Pixium") and related financial contingencies.
Key Financial Metrics and Contingencies
The filing does not provide standard financial metrics such as revenue, profit, cash flow, or debt levels. Instead, it details specific contingent liabilities arising from the terminated agreement:
- Termination Fee: The Company plans to pay a $1,000,000 liquidated damages fee as stipulated in the Memorandum of Understanding (MOU).
- Disputed Damages: Pixium has rejected the Company's settlement offers and demanded 6 million Euros in damages, indicating an intent to pursue litigation.
- Disputed Fees: The Company received an invoice from placement agent Oppenheimer & Co. Inc. for $1,860,684.41, which the Company believes is without merit.
Material Changes and Events
On April 1, 2021, the Company's Board of Directors determined that the business combination with Pixium was not in the best interest of shareholders and formally terminated the MOU. Following the termination, Pixium declared the action wrongful and initiated a dispute over damages. Additionally, the Company faces a claim for placement agent fees related to a financing round that was intended to support the now-terminated combination.
Outlook, Risks, and Management Commentary
Management is seeking an amicable resolution regarding termination amounts but notes that no assurance can be given that such a resolution will be reached. The Company has offered either the $1,000,000 liquidated damages or a patent license to settle matters. Significant risks include potential litigation from Pixium seeking 6 million Euros and the disputed $1.86 million fee claim from Oppenheimer. The filing does not provide forward-looking guidance on revenue or operational outlook.
Investor Verification Checklist
- Verify the status of the litigation risk regarding Pixium's demand for 6 million Euros.
- Confirm the Company's legal stance and potential liability regarding the $1,860,684.41 invoice from Oppenheimer & Co. Inc.
- Monitor cash flow impacts from the planned $1,000,000 termination payment.
- Review subsequent filings for updates on the settlement negotiations or court proceedings.